SCHEMBL20120320

SCHEMBL20120320

OCCCO[C@H]1C[C@@H](OCc2ccccc2)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSL P07711 1/20 0.44
▸ CTSB P07858 1/20 0.44
▸ CTSK P43235 1/20 0.44
▸ EPHX2 P34913 2/20 0.41
▸ LTA4H P09960 1/20 0.41
▸ NAAA Q02083 3/20 0.41
▸ BCHE P06276 1/20 0.40
▸ OPRM1 P35372 2/20 0.40
▸ OPRL1 P41146 2/20 0.40
▸ DPP4 P27487 1/20 0.40
▸ PDE4D Q08499 1/20 0.39
▸ TMEM97 Q5BJF2 1/20 0.38
▸ CARM1 Q86X55 1/20 0.38
▸ PRMT6 Q96LA8 1/20 0.38
▸ SIGMAR1 Q99720 1/20 0.38
▸ PRMT8 Q9NR22 1/20 0.38
▸ HRH3 Q9Y5N1 1/20 0.38
▸ PDPK1 O15530 1/20 0.38
▸ MTOR P42345 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20120322 1.00 CTSL (0.44) CTSLCTSBCTSKEPHX2LTA4H
SCHEMBL23205312 0.90 CTSL (0.46) CTSLCTSBCTSKEPHX2NAAA
SCHEMBL21421849 0.90 CTSL (0.46) CTSLCTSBCTSKEPHX2NAAA
SCHEMBL22835923 0.83 PDE4D (0.41) CTSLCTSBCTSKEPHX2LTA4H
SCHEMBL22835922 0.83 PDE4D (0.41) CTSLCTSBCTSKEPHX2LTA4H
SCHEMBL20197146 0.82 PDPK1 (0.54) EPHX2LTA4HBCHEPDPK1MTOR
SCHEMBL20197403 0.82 PDPK1 (0.54) EPHX2LTA4HBCHEPDPK1MTOR
SCHEMBL20197147 0.82 PDPK1 (0.54) EPHX2LTA4HBCHEPDPK1MTOR
SCHEMBL27133585 0.81 LIPG (0.37) CTSLCTSBCTSKEPHX2BCHE
SCHEMBL20128961 0.81 TSHR (0.46) CTSLCTSBCTSKLTA4HNAAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559486-B2 Tau-protein targeting compounds and associated methods of use ARVINAS OPERATIONS, INC. (US) 2026-02-24 — — US disclosed
US-20240217962-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2024-07-04 — — US disclosed
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 — — US disclosed
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 — — US disclosed
US-11707452-B2 Modulators of alpha-synuclein proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2023-07-25 — — US disclosed
US-20220315575-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2022-10-06 — — US disclosed
US-11458123-B2 Tau-protein targeting PROTACs and associated methods of use ARVINAS OPERATIONS, INC. (US) 2022-10-04 — — US disclosed
WO-2021011913-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2021-01-21 — — WO disclosed
WO-2020041331-A1 PROTEOLYSIS TARGETING CHIMERIC (PROTAC) COMPOUND WITH E3 UBIQUITIN LIGASE BINDING ACTIVITY AND TARGETING ALPHA-SYNUCLEIN PROTEIN FOR TREATING NEURODEGENERATIVE DISEASES ARVINAS OPERATIONS, INC. (US) 2020-02-27 — — WO disclosed
WO-2018102067-A2 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE Arvinas, Inc. (US) 2018-06-07 — — WO disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 — — US disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315575-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE VHL, CRBN, MAPT CTSL 3340/4885CTSB 2539/4885CTSK 2852/4885
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN CTSL 3582/4885CTSB 2723/4885CTSK 3042/4885
US-11458123-B2 Tau-protein targeting PROTACs and associated methods of use CRBN, VHL, UBQLN2 CTSL 2961/4885CTSB 2742/4885CTSK 2765/4885
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE CRBN, VHL, UBQLN2 CTSL 2961/4885CTSB 2742/4885CTSK 2765/4885
US-20240217962-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE VHL, CRBN, MAPT CTSL 3340/4885CTSB 2539/4885CTSK 2852/4885
US-12559486-B2 Tau-protein targeting compounds and associated methods of use UBQLN2, UBQLN1, CRBN CTSL 3380/4885CTSB 3026/4885CTSK 2959/4885
US-11707452-B2 Modulators of alpha-synuclein proteolysis and associated methods of use UCHL1, ADRM1, CRBN CTSL 1648/4885CTSB 881/4885CTSK 1607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback